Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
Publication/Presentation Date
6-1-2012
Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. The panel made 3 significant updates to the guidelines: 1) more detail was added regarding multiphase CT techniques for diagnosis and staging of pancreatic cancer, and pancreas protocol MRI was added as an emerging alternative to CT; 2) the use of a fluoropyrimidine plus oxaliplatin (e.g., 5-FU/leucovorin/oxaliplatin or capecitabine/oxaliplatin) was added as an acceptable chemotherapy combination for patients with advanced or metastatic disease and good performance status as a category 2B recommendation; and 3) the panel developed new recommendations concerning surgical technique and pathologic analysis and reporting.
Volume
10
Issue
6
First Page
703
Last Page
713
ISSN
1540-1413
Published In/Presented At
Tempero, M. A., Arnoletti, J. P., Behrman, S. W., Ben-Josef, E., Benson, A. B., 3rd, Casper, E. S., Cohen, S. J., Czito, B., Ellenhorn, J. D., Hawkins, W. G., Herman, J., Hoffman, J. P., Ko, A., Komanduri, S., Koong, A., Ma, W. W., Malafa, M. P., Merchant, N. B., Mulvihill, S. J., Muscarella, P., 2nd, … National Comprehensive Cancer Networks (2012). Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : JNCCN, 10(6), 703–713. https://doi.org/10.6004/jnccn.2012.0073
Disciplines
Medicine and Health Sciences
PubMedID
22679115
Department(s)
Hematology-Medical Oncology Division
Document Type
Article